Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study

Rebecca Pedersini^a Lucia Vassalli^a Melanie Claps^b Antonella Tulla^b
Filippo Rodella^b Salvatore Grisanti^b Vito Amoroso^b Elisa Roca^b
Edda Lucia Simoncini^c Alfredo Berruti^b

^aBreast Unit-Oncology Department, Spedali Civili Hospital, Brescia, Italy; ^bOncology Department, Spedali Civili Hospital, Brescia, Italy; ^cBreast Unit, Spedali Civili Hospital, Brescia, Italy

Keywords

Eribulin · Metastatic breast cancer · Real-world practice · Progression-free survival · Overall survival · Safety

Abstract

Objectives: The aim of this study was to investigate efficacy and safety of eribulin in heavily pretreated patients with advanced breast cancer (BC) in a real-life setting. **Methods:** This retrospective monocentric study included patients with HER-2-negative metastatic BC, pretreated with anthracyclines and taxanes, who were referred to the Oncology Department of Spedali Civili of Brescia from May 2012 to April 2017. Patients received the same dose of eribulin as that used in the EMBRACE trial: 1.4 mg/m² on days 1 and 8 every 21 days. **Results:** In a total of 53 patients, 32% obtained a partial response, 11% a stable disease, and 43% a clinical benefit (CB). After a median follow-up of 36 months, median progression-free survival (PFS) was 4.7 months and median overall survival (OS) 13.53 months. Median PFS was significantly longer in patients who reported a CB compared to those with no CB, while survival outcomes (PFS and OS) were better in patients who received >6 cycles of eribulin. Eribulin showed a good tolerability profile with acceptable toxicities,

similar to those reported in EMBRACE. **Conclusions:** Our experience in a real-world setting confirms the activity, efficacy, and good tolerability profile of eribulin in heavily pretreated BC patients.

© 2018 The Author(s)

Published by S. Karger AG, Basel

Introduction

In Italy, breast cancer (BC) represents 29% of all female cancers; it is the leading cause of neoplastic death in women, and long-term survival of patients with advanced BC (ABC) has only minimally improved despite the availability of several active agents [1–3].

Anthracyclines and/or taxanes are the most commonly used drugs in first-line metastatic settings, in patients with human epidermal growth factor 2 (HER2)-negative BCs. Other drugs such as vinorelbine, gemcitabine, nab-paclitaxel, capecitabine, and liposomal anthracyclines are used in this setting; however, no standard of care exists [4–8]. Eribulin mesylate is a structurally simplified synthetic analogue of halichondrin B (a natural product isolated from the marine sponge *Halichondria okadaei*), which inhibits the growth phase of microtubule dynamics

and sequesters tubulin into nonproductive aggregates. This results in the inhibition of microtubule polymerization, without affecting depolymerization, and inducing an irreversible mitotic block at G2-M phases and consequent apoptosis [9–11]. Three phase II trials evaluated the efficacy and safety of eribulin in ABC patients, showing encouraging results in terms of activity and tolerability [12–14]. A randomized phase III trial (EMBRACE) demonstrated overall survival (OS) advantage of eribulin compared to treatment of physician's choice in patients with heavily pretreated BC, with manageable toxicity [15]. The results observed in the pivotal EMBRACE study led to the regulatory approval of eribulin as treatment in metastatic BC patients who had progressed after at least 2 chemotherapy lines, including anthracyclines and taxanes in either an adjuvant or metastatic setting.

This drug is now being widely employed outside of clinical trials in Italy, including our center, as third or further line of treatment. On this basis, we conducted a real-life retrospective study investigating the efficacy and safety of eribulin in heavily pretreated ABC patients treated at our center.

Patients and Methods

This monocentric study was conducted at the Oncology Department of Spedali Civili of Brescia from May 2012 to April 2017.

Our analysis included metastatic BC patients, with a HER2-negative status, pretreated with anthracyclines and taxanes, and with 2 or more previous chemotherapy lines for advanced disease; patients with HER2 overexpression or amplification were excluded. Inclusion criteria also comprised Eastern Cooperative Oncology Group (ECOG) grade 2 or less, a life expectancy of more than 12 weeks, and adequate organ and hematological functions.

Treatment schedule was the same as that used in the registered trial, namely eribulin mesilate 1.4 mg/m² administered intravenously during 2–5 min on days 1 and 8 of a 21-day cycle. Treatment continued until disease progression, unacceptable toxicity, and patient's or physician's request to discontinue.

Adverse events (AE) were assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, version 4), and treatment efficacy was evaluated by conventional RECIST criteria every 3 weeks or whenever clinically indicated.

All clinical and histopathological information as well as all AEs, and their correlation with eribulin treatment, were recorded.

Statistical Analysis

A retrospective review of clinical and treatment data for all the patients was carried out, and data were entered into a database for data collection. The standard descriptive statistics was used for both continuous and discrete variables. The purpose of the study was to evaluate the clinical outcomes of the treated patients in terms of objective response rate (ORR) and progression-free sur-

Table 1. Patient and tumor characteristics (*n* = 53)

Median age, years	62 (range 30–79)
Median ECOG	
PS 0–1	41 (77%)
PS 2	12 (13%)
Dominant disease site	
Viscera	52 (98%)
Bone alone	1 (2%)
Sites of metastases	
Liver	30 (55%)
Lung	11 (21%)
Bone	9 (17%)
Others	3 (7%)
Histology	
ER- and PgR-positive	45 (85%)
Triple negative	8 (15%)
Median prior lines of chemotherapy for advanced disease	4 (range 2–7)
Number of prior chemotherapies for advanced disease	
1–3	17 (32%)
>3	36 (68%)
Previous chemotherapy for advanced disease	
Taxanes	54 (100%)
Vinorelbine	28 (52%)
Eribulin cycles administered	5 (range 2–15)

ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; PgR, progesterone receptor; PS, performance status.

vival (PFS), and the correlation with biological features, safety, and OS. Response rate included complete response (CR) and partial response (PR); clinical benefit (CB) was defined as CR + PR + disease stabilization lasting at least 24 weeks. PFS was defined as the interval from the start of therapy with eribulin to the date of progression. Patients without progression were censored. OS was calculated as the interval from the start of therapy with eribulin to the date of death or the date of last follow-up evaluation. PFS and OS were calculated by the Kaplan-Meier method.

Results

Our analysis included 53 metastatic and pretreated BC patients referred to our center, who received at least 2 eribulin cycles.

The baseline characteristics of the patients are reported in Table 1. Median age was 61 years (range 39–81) and 77% of patients had an ECOG of 0–1. In terms of BC subtypes, 45 patients (85%) had endocrine-sensitive disease and 8 patients (15%) had a triple-negative BC. Fifty-two (98%) patients had visceral metastases, 1 patient (2%) had only bone involvement, and 7 patients (14%) presented

Table 2. Toxicity according to National Cancer Institute Common Terminology Criteria version 4.0

Toxicity	G1–2, <i>n</i> (%)	G3–4, <i>n</i> (%)
Neutropenia	2 (4)	2 (4)
Anemia	1 (2)	–
Fatigue	8 (15)	–
Neurotoxicity	2 (4)	–
Dermatological toxicity	1 (2)	–
Hypertransaminasemia	2 (4)	–

Table 3. Objective response in 53 evaluable patients

Responses	Patients, <i>n</i> (%)	95% CI
Partial response	17 (32)	±12.6
Stable disease	6 (11)	–
Progressive disease	30 (57)	–
Clinical benefit (SD+PR)	23 (43)	±13.3

CI, confidence interval; PR, partial response; SD, stable disease.

Table 4. Clinical benefit according to other variables

Variable	Disease progression	Clinical benefit	<i>p</i>
Histology			
Hormone receptor positive	25	20	0.715
Triple negative	5	3	
Sites of metastases			
Liver	17	13	0.139
Lung	9	2	
Bone	3	6	
Others	1	2	
Previous therapies			
1–3	10	7	0.083
>3	20	16	

Table 5. Survival outcome

Outcome	Mean (95% CI)	Median (95% CI)
PFS	6.8 (4.95–8.64)	4.7 (3.32–6.14)
OS	14.97 (11.79)	13.53 (9.39–17.67)

OS, overall survival; PFS, progression-free survival.

metastases of the central nervous system. Patients had received a median of 4 (range 2–7) prior lines of chemotherapy for advanced disease. Seventeen patients (32%) had been treated with less than 3 lines of chemotherapy, while the remaining 36 patients (68%) had received more than 3 and up to 7 previous chemotherapy lines, excluding the adjuvant setting. All patients had received previous anthracycline and taxane treatment, and vinorelbine had been used in 52% of the population.

Patients received a median of 5 cycles of eribulin (range, 2–11), with 15 patients (28%) receiving more than 6 cycles, and the remaining 38 patients (72%) 6 cycles or less. Regarding eribulin dose, 43 patients (81%) started treatment at a lower dose (75%), and 22% started and continued treatment at 50% of the standard dose.

Hematological and other toxicities are reported in Table 2. Grade 4 (G4) neutropenia occurred in 2 patients, grade 2 (G2) neutropenia occurred in 2 patients, and G2 anemia was reported in 1 patient. Regarding nonhematological toxicities, 8 patients (15%) experienced G2 asthenia, 2 patients (4%) experienced G2 peripheral neuropathy, and 2 patients (4%) reported increase in transaminases. None of the patients suffered from mucositis. Of note, the toxicity profile was similar in patients aged 70 years or more (8 patients, 14%) as compared to the younger population.

All the 53 patients enrolled in the study were evaluated for response (Table 3). No patient achieved a CR, and 17 patients obtained a PR, with an ORR of 32%. Stable disease was observed in 6 patients (11%) and CB was reported in 23 patients (43%). No difference in CB rate was observed in our cohort of unselected patients according to prognostic factors such as tumor histology, site of metastasis, or number of previous therapies (Table 4).

Table 5 summarizes median PFS and OS recorded in the study. At the time of the present analysis, 16 patients (30%) are still alive. After a median follow-up of 36 months, median PFS was 4.7 months (95% confidence interval [CI] 3.32–6.14 months) (Table 5; Fig. 1a), and median OS was 13.53 months (95% CI 9.39–17.67 months) (Table 5; Fig. 1b).

Table 6 reports survival outcomes according to different patients' prognostic features such as BC subtype, location of metastases, CB, number of previous therapies, and number of eribulin cycles. Median PFS was significantly longer in patients who reported CB, compared to those who did not obtain a CB (7.8 vs. 3 months, $p = 0.0001$), and in patients who received more than 6 cycles of eribulin compared to those who received 6 cycles or less (8.73 vs. 3.06 months, $p = 0.001$). Median OS was longer in pa-

Fig. 1. Median progression-free survival (PFS; **a**) and median overall survival (OS; **b**).

tients who received more than 6 cycles of eribulin compared to those who received 6 cycles or less (20.3 vs. 9.5 months, $p = 0.034$) (Fig. 1b).

Discussion

Despite the advances obtained over the last 2 decades in the treatment of BC, both in terms of efficacy and tolerability, the prognosis for ABC patients remains poor. Until now, treatment guidelines have not clearly identified a specific regimen or single agent to be used in the advanced setting after the first-chemotherapy line. Recent retrospective studies have suggested that administration of chemotherapy beyond the third line can lead to a potential gain in terms of outcome, since each line can contribute to survival prolongation [16–21]. It should be noted, however, that patients that receive several chemotherapy lines might be identified as having a better prognosis independently from the treatment administered.

Our experience in the use of eribulin in the real-world practice confirms the activity and efficacy of this drug in heavily pretreated patients. In fact, PR and disease stabilization were observed in 32 and 11% of the patients, respectively, and CB was obtained in 43% of the study population. The median PFS and OS registered during the study were 4.7 and 13.5 months, respectively, an interest-

ing result, especially considering the heavily pretreated status of our patients and their poor prognostic features. As expected, PFS was longer in subjects obtaining a CB as compared to those who did not, and survival outcomes were better in patients who received more than 6 cycles of eribulin chemotherapy.

The results of the EMBRACE trial, in which eribulin was compared with the best treatment strategy chosen by the investigator, were encouraging, as they showed a survival advantage that had never been previously reported with a single agent in a cohort of very heavily pretreated patients [15]. Interestingly, a pooled analysis of 2 phase III studies on eribulin revealed that the OS benefit was consistent in all BC molecular subtypes, with triple-negative patients obtaining the largest benefit [22]. Eribulin activity in heavily pretreated patients in terms of ORR, CB, PFS, and OS has been further confirmed in other retrospective analyses conducted in different countries in a clinical practice setting [23–29]. In our experience on the use of eribulin in a real world heavily pretreated population, we observed similar outcomes to those reported in the EMBRACE trial (OS 13.5 months). Similarly the ORR and OS obtained with eribulin were comparable between triple-negative and hormone-positive subtypes, in line with the results reported by other colleagues [23, 30]. The results of our study, in agreement with other experiences, confirm that eribulin can be active regardless of chemo-

Table 6. Survival outcome and other variables

Variable	Median PFS (95% CI)	Median OS (95% CI)
Histology		
Hormone receptor positive	4.6 (2.70–6.63)	13.5 (9.39–17.67)
Triple negative	4.7 (0.0–11.56)	7.43 (3.39–11.47)
<i>p</i>	0.29	0.488
Sites of metastases		
Liver	4.66 (2.16–7.16)	9.6 (7.56–11.77)
Lung	3.7 (3.20–4.19)	12.3 (0.0–24.81)
Bone	2.52 (2.84–12.7)	15.5 (1.89–29.1)
Others	1.87 (3.25–10.61)	19.5 (9.95–29)
<i>p</i>	0.86	0.35
CB		
SD+RP	3 (2.24–3.76)	9.56 (6.43–12.69)
PD	7.8 (5.86–9.73)	19.5 (12.56–26.44)
<i>p</i>	0.000	0.119
Previous therapy		
1–3	4.73 (0.55–8.91)	13.5 (5.15–21.9)
>3	3.7 (1.47–5.92)	10.3 (4.93–15.66)
<i>p</i>	0.26	0.683
Cycles, <i>n</i>		
≤6	3.06 (2.30–3.83)	9.5 (6.67–12.46)
>6	8.73 (7.10–10.35)	20.3 (14–26.5)
<i>p</i>	0.001	0.034

therapy line [24, 25] and seems to be more active in patients who received chemotherapy until progression (more than 6 cycles).

In our population, eribulin showed a good tolerability profile, and patient's toxicities were acceptable and lower compared to those registered in the EMBRACE trial and in other studies [23–29]. This aspect deserves further consideration, as one possible reason for this lower toxicity is that eribulin chemotherapy was started at a lower dose (75%) and that 22% of the patients maintained during the whole study a reduced dosage treatment with 50% of the standard dose. The most common G3 and G4 AE was neutropenia; alopecia was the most frequent AE (85%), and patients also suffered from fatigue (15%) and neurosensory toxicity (4%). Of note, 52% of the patients had already received vinorelbine, and all the subjects had been previously treated with a taxane-based chemotherapy, agents known for causing peripheral neuropathy [31]. These findings could suggest that eribulin may not aggravate peripheral neuropathy toxicity in patients pretreated with neurotoxic drugs, as reported by Fabi et al. [26]. Moreover, no differences in toxicity were observed between young and

elderly patients, considering that 36% of the patients were 65 years or older.

Despite all the limitations implicit in a retrospective, real-life design, our study of eribulin treatment in an unselected highly pretreated patient population achieved similar results to those reported in clinical studies in terms of both activity and toxicity. Further, prospective studies investigating the effects of eribulin treatment in metastatic BC patients are warranted.

Acknowledgements

Editorial assistance for the preparation of this manuscript was provided by Aurora Mirabile, MD, Luca Giacomelli, PhD, and Aashni Shah on behalf of Content Ed Net; this assistance was funded by Eisai. The supporting company was not offered the opportunity to revise the manuscript and had no role in the decision to submit.

Disclosure Statement

The authors declare that they have no conflicts of interest.

References

- 1 Associazione Italiana Registro Tumori (AIRTUM): I numeri del cancro in Italia. 2016 <http://www.registri-tumori.it>
- 2 Siegel RL, Miller KD, Jemal A: Cancer statistics 2015. *CA Cancer J Clin* 2015;65:5–29.
- 3 Rosa M: Advances in the molecular analysis of breast cancer: pathway toward personalized medicine. *Cancer Control* 2015;22:211–219.
- 4 Wang Y, Liu J, Jia W, Li S, Rao N, Su F, Liu Q, Yao H: Comparison of the therapeutic efficacy of the early and the delayed use of vinorelbine-based regimens for patients with advanced breast cancer. *Chemotherapy* 2017; 62:71–79.
- 5 Modi S, Currie VE, Seidman AD, Bach AM, Panageas KS, Theodoulou M, Moasser MM, D'Andrea GM, Lake DE, Choi J, Norton L, Hudis CA: A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. *Clin Breast Cancer* 2005;6:55–60.
- 6 Li J, Ren J, Sun W: Systematic review of ixabepilone for treating metastatic breast cancer. *Breast Cancer* 2017;24:171–179.
- 7 Palumbo R, Sottotetti F, Bernardo A: Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients? *Ther Adv Med Oncol* 2016;8:209–229.
- 8 Al-Batran SE, Guntner M, Pauligk C, Scholz M, Chen R, Beiss B, Stopatschinskaja S, Lerbs W, Harbeck N, Jäger E: Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials. *Br J Cancer* 2010;103: 1518–1523.
- 9 Jordan MA, Kamath K, Manna T, Okounieva T, Miller HP, Davis C, Littlefield BA, Wilson L: The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. *Mol Cancer Ther* 2005;4:1086–1095.
- 10 Smith JA, Wilson L, Azarenko O, Zhu X, Lewis BM, Littlefield BA, Jordan MA: Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. *Biochemistry* 2010;49:1331–1337.
- 11 Towle MJ, Salvato KA, Wels BF, Aalfs KK, Zheng W, Seletsky BM, Zhu X, Lewis BM, Kishi Y, Yu MJ, Littlefield BA: Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. *Cancer Res* 2011;71:496–505.
- 12 Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roché H, Bachelot T, Awada A, Paridaens R, Goncalves A, Shuster DE, Wanders J, Fang F, Gurnani R, Richmond E, Cole PE, Ashworth S, Allison MA: Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. *J Clin Oncol* 2010;28:3922–3928.
- 13 Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, Wright J, Tan AR, Dacosta NA, Chuang E, Smith J, O'Shaughnessy J, Shuster DE, Meneses NL, Chandrawansa K, Fang F, Cole PE, Ashworth S, Blum JL: Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. *J Clin Oncol* 2009; 27:2954–2961.
- 14 Aogi K, Iwata H, Masuda N, Mukai H, Yoshida M, Rai Y, Taguchi K, Sasaki Y, Takashima S: A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. *Ann Oncol* 2012;23:1441–1448.
- 15 Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators: Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. *Lancet* 2011;377:914–923.
- 16 Tacca O, LeHeurteur M, Durando X, Mouret-Reynier MA, Abrial C, Thivat E, Bayet-Robert M, Penault-Llorca F, Chollet P: Metastatic breast cancer: overall survival related to successive chemotherapies. What do we gain after the third line? *Cancer Invest* 2009;27:81–85.
- 17 Bernardo G, Palumbo R, Poggi G, Barbardo A, Teragni C, Frascaroli M, Amatu A, Montagna B, Tagliaferri B, Sottotetti F, Albanese D, Strada MR: Beyond the second line chemotherapy in metastatic breast cancer: when stop the treatment between science and conscience. *Cancer Res* 2010;70:446s.
- 18 Planchat E, Abrial C, Thivat E, Mouret-Reynier MA, Kwiatkowski F, Pomel C, Wang-Lopez Q, Chollet P, Nabholz JM, Durando X: Late lines of treatment benefit survival in metastatic breast cancer in current practice? *Breast* 2011;20:574–578.
- 19 Dufresne A, Pivrot X, Tournigand C, Facchini T, Altweegg T, Chaigneau L, De Gramont A: Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. *Breast Cancer Res Treat* 2008;107:275–279.
- 20 Palumbo R, Sottotetti F, Riccardi A, Teragni C, Pozzi E, Quaquarini E, Tagliaferri B, Bernardo A: Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians. *Ther Adv Med Oncol* 2013;5:334–335.
- 21 Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J: Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. *J Clin Oncol* 2015;33:594–601.
- 22 Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman PA, Awada A: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. *Breast Cancer Res Treat* 2014;148:553–561.
- 23 Gamucci T, Michelotti A, Pizzuti L, Mentuccia L, Landucci E, Sperduti I, Di Lauro L, Fabi A, Tonini G, Sini V, Salesi N, Ferrarini I, Vaccaro A, Pavese I, Veltri E, Moscetti L, Marchetti P, Vici P: Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study. *J Cancer* 2014;5:320–327.
- 24 Rossi S, Cassano A, Strippoli A, Schinzari G, D'Argento E, Basso M, Barone C: Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapies. *Drugs Context* 2017;6:212506.
- 25 Watanabe J: Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review. *Springerplus* 2015;4:625.
- 26 Fabi A, Moscetti L, Ciccarese M, Caramanti M, Salesi N, La Verde N, Russillo M, Generali D, Scandurra G, Vari S, Pacetti U, Cognetti F, Giannarelli D: Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice. *Future Oncol* 2015;11:431–438.
- 27 Quaquarini E, Sottotetti F, D'Ambrosio D, Malovini A, Morganti S, Marinello A, Pavese L, Frascaroli M: Eribulin across multiple lines of chemotherapy: a retrospective study on quality of life and efficacy in metastatic breast cancer patients. *Future Oncol* 2017;13:11–23.
- 28 Prestifilippo A, Grippaldi D, Blanco G, Memeo L, Puliafito I, Giuffrida D: Eribulin efficacy based on type of metastatic site: a real-life study in heavily pretreated metastatic breast cancer. *Future Oncol* 2017;13:5–10.
- 29 Morriti M, Iodice G, Melaccio A, D'Onofrio L, Bergnolo P, Boggione A, Comandone A, Molinaro P, Garigliano D: Long-term treatment with eribulin in heavily pretreated women with metastatic breast cancer: a case series. *Future Oncol* 2017;13:25–33.
- 30 Kessler L, Falato C, Margolin S, Bergh J, Foukakis T: A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden. *Acta Oncol* 2015;54:522–529.
- 31 Carlson K, Ocean AJ: Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach. *Clin Breast Cancer* 2011;11:73–81.